Stockreport

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients [Yahoo! Finance]

Artelo Biosciences, Inc.  (ARTL) 
US:NASDAQ Investor Relations: artelobio.com/investors
PDF Artelo Biosciences Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology First patien [Read more]